Skip to main content
ETON
NASDAQ Life Sciences

Eton Pharmaceuticals CEO Sells $3.8M in Company Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$30.45
Mkt Cap
$834.097M
52W Low
$13.085
52W High
$35.66
52W Position info
133% above low
Off High info
15% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

ETON has more than doubled off its 52-week low of $13.085.

Summary

Eton Pharmaceuticals' President and CEO, Sean Brynjelsen, sold $3.8 million worth of company stock, a notable transaction following recent positive financial and product news.


Key Events · Ownership and Investor Activity · ETON

  • CEO Sells Significant Stake

    President and CEO Sean Brynjelsen disposed of 120,000 shares of common stock in two open market transactions on May 28, 2026, for a total value of $3,825,717.

  • Timing Amidst Positive News

    This substantial insider sale occurs shortly after Eton Pharmaceuticals reported strong Q1 2026 results, including a 73% increase in product sales and profitability, and a stock surge following the relaunch of Hemangeol.

  • Post-Transaction Holdings

    Following these transactions, Sean Brynjelsen directly holds 833,842 shares of Eton Pharmaceuticals common stock.


Analysis · ETON · Life Sciences

Sean Brynjelsen, the President and CEO of Eton Pharmaceuticals, sold over $3.8 million worth of company stock. This significant sale by a key executive comes shortly after the company reported strong Q1 2026 results, including increased product sales and profitability, and a stock surge following product relaunches. While the company has shown positive operational momentum, a large insider sale by the CEO can be interpreted as a lack of conviction or a move to lock in gains, potentially raising questions about future outlook despite recent successes.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ETON was trading at $30.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $834.1M. The 52-week trading range was $13.09 to $35.66. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ETON - Latest Insights

ETON
Nov 06, 2026, 9:04 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $58.86
Real-time Price: $63.68 info
Change: +$4.82 (+8%) info
Market Cap: $1.84B info
ETON
Nov 05, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $57.90
Real-time Price: $63.68 info
Change: +$5.78 (+10%) info
Market Cap: $1.84B info
ETON
Nov 05, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $56.06
Real-time Price: $63.68 info
Change: +$7.62 (+14%) info
Market Cap: $1.84B info
ETON
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $47.15
Real-time Price: $63.68 info
Change: +$16.53 (+35%) info
Market Cap: $1.84B info
ETON
Nov 05, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $47.15
Real-time Price: $63.68 info
Change: +$16.53 (+35%) info
Market Cap: $1.84B info